Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data 
Asian Currencies Steady as Markets Await U.S. Inflation Data 
China Inflation Cools in July as CPI Misses Forecast, PPI Deflation Eases 
US Stock Futures Flat as Iran Strait of Hormuz Demands Fuel Oil Concerns 
Judge Approves Anthropic’s $1.5 Billion AI Copyright Settlement With Authors 
California ICE Detention Center Found to Have Inadequate Medical Care, Court Monitor Says 
Australian Shares Fall as Westpac Slides, Miners Gain Ahead of RBA Decision 
U.S. Unseals Charges Against Five Alleged CJNG Leaders, Raises Reward for New Cartel Chief 
Japan Executives Warn Weak Yen and Currency Volatility Threaten Economy 
Brazil Supreme Court Approves Probe Into Lula’s Son Over Health Ministry Lobbying Claims 
Asian Stocks Rise as Weak US Jobs Data Eases Fed Rate Hike Fears 
US Judge Dismisses Gautam Adani Criminal Charges 
BOJ Signals Faster Rate Hikes as Inflation Risks Raise September Move Odds 
Brazil Supreme Court Tightens Jair Bolsonaro House Arrest Ahead of Election 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
US Dollar Near Two-Month Low as Markets Await Inflation Data 
DOJ Subpoenas New York Times Freelancer Over North Korea Military Report 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
